Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing
Amneal Pharmaceuticals posted its fourth straight earnings beat, with Q3 revenue up 10%, raised FY26 guidance and an expanding biosimilar…
NASDAQ
Cap as of Nov 16 1 story
Get AMRX news in Claude, ChatGPT or your own code. See plans
Amneal Pharmaceuticals posted its fourth straight earnings beat, with Q3 revenue up 10%, raised FY26 guidance and an expanding biosimilar…